The verdict
Our read at a glance.
Whether GDF-11 declines with age and rejuvenates tissue, or increases with age and inhibits regeneration - the literature has said both.
- The signal
- The original claims were high profile: GDF-11 was reported to reverse age-related cardiac hypertrophy and to improve skeletal muscle regeneration and function in old mice. The contradiction came from work showing that GDF-11 levels actually increase with age and that GDF-11 inhibits skeletal muscle regeneration, with much of the discrepancy attributed to assays and reagents unable to distinguish GDF-11 from myostatin, which is more than ninety per cent identical in its mature domain. Subsequent work has not produced a clean resolution. There is no human efficacy trial of GDF-11 for any indication.
- The unknown
- Whether any of the original rejuvenation findings survive with reagents that reliably separate GDF-11 from myostatin, and in which direction the true age-related change runs.
- Our read
- Kept on the Watchlist as a lesson rather than a candidate. Two prestigious papers, a contradicting paper, and a measurement problem underneath all three. When a field cannot agree on whether a molecule goes up or down with age, nobody should be injecting it.
The mechanism
How it works.
GDF-11 is a member of the TGF-beta superfamily and a close relative of myostatin, which is GDF-8. Both are secreted as latent precursors, activated by cleavage, and both signal through activin type II receptors to SMAD2/3, the pathway that restrains muscle growth. That family resemblance is central to the controversy: the mature domains are so similar that antibodies and assays raised against one can detect the other, so a study reporting that GDF-11 falls with age may have been measuring a combined signal in which myostatin dominates. The proposed rejuvenation mechanism was that restoring a declining circulating factor would restore regenerative signalling in old tissue. The competing account is that GDF-11, like myostatin, suppresses muscle regeneration, so raising it in an old animal would make things worse.
Safety & regulatory boundary
The consequential part.
Not an approved drug anywhere and never tested in humans for these claims. It is a TGF-beta superfamily member closely related to myostatin, so systemic administration would be expected to affect muscle, cardiac and other tissues in ways that have not been characterised in people. Material sold as GDF-11 is a research reagent with no human manufacturing standard.
What's next
What we're watching.
Any study using validated, myostatin-discriminating assays, which is the methodological fix the whole dispute turns on.
Context
Why this is discussed.
It was the molecular explanation for the young-blood parabiosis experiments, it was reported everywhere as the anti-ageing factor, and it is sold as a research peptide on that basis.
The evidence base
20 cited references.
Registered trials8
ClinicalTrials.gov · NA · ACTIVE_NOT_RECRUITING · 2025-05-19
ClinicalTrials.gov · PHASE2 · RECRUITING · 2022-12-09
ClinicalTrials.gov · PHASE1 · RECRUITING · 2026-05-24
ClinicalTrials.gov · PHASE2 · NOT_YET_RECRUITING · 2026-03-14
ClinicalTrials.gov · NA · COMPLETED · 2022-10-25
ClinicalTrials.gov · NA · RECRUITING · 2025-01-17
ClinicalTrials.gov · NA · RECRUITING · 2023-02-20
ClinicalTrials.gov · COMPLETED · 2022-01-01
Indexed literature (PubMed)12
Mendelsohn AR et al. · Rejuvenation Res · 2013
Laviano A · N Engl J Med · 2014
Conboy IM et al. · Aging (Albany NY) · 2015
Castellano JM · Gerontology · 2019
Rochette L et al. · Arch Cardiovasc Dis · 2023
Kaiser J · Science · 2015
Kaiser J · Science · 2014
Bitto A et al. · Cell Metab · 2014
Ma J et al. · Brain Res Bull · 2019
Katsimpardi L et al. · Science · 2014
Conese M et al. · Open Med (Wars) · 2017
Rochette L et al. · Int J Mol Sci · 2018
Keep reading